JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Case Report
Ponatinib-induced dilated cardiomyopathy: a case report
Abstract
Ponatinib is a third-generation tyrosine kinase inhibitor with potent efficacy in the treatment of acute and chronic leukemia. Despite having an effective and sustained activity in all BCR-ABL1 mutations, it may cause cardiovascular adverse effects. Here we report a 56-year-old male patient with Chronic myeloid leukemia and no prior cardiac disorder who developed acute heart failure under ponatinib treatment. Guideline-recommended medical treatment for heart failure was initiated. Coronary angiography to exclude ischemic heart disease revealed no coronary stenosis. Cardiac magnetic resonance imaging showed findings consistent with non-ischemic dilated cardiomyopathy. After interruption of ponatinib treatment, cardiac evaluation showed improvement in left ventricular ejection fraction. Patients on Ponatinib therapy should be closely monitored for signs and symptoms of heart failure.

Keywords : Cardio-Oncology, dilated cardiomyopathy, heart failure

Download Article


1. de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene istranslocated to the Philadelphia chromosome in chronic myelocyticleukaemia. Nature. 1982;300(5894):765-767. doi:10.1038/300765a0
2. Pasvolsky O, Leader A, Iakobishvili Z, Wasserstrum Y, Kornowski R,Raanani P. Tyrosine kinase inhibitor associated vascular toxicity inchronic myeloid leukemia. Cardio-Oncology. 2015;1(1):1-10 doi:10.1186/s40959-015-0008-5
3. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinibin Philadelphia chromosome-positive leukemias. N Engl J Med.2013;369(19):1783-1796. doi:10.1056/NEJMoa1306494
4. Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines forthe management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626 doi:10.1093/eurheartj/ehad194
5. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safetyin Philadelphia chromosome-positive leukemia: final 5-year resultsof the phase 2 PACE trial. Blood. 2018;132(4):393-404. doi:10.1182/blood-2016-09-739086
6. Cortes JE, Deininger MW, Lomaia E, et al. Three-year update from theoptic trial: a dose-optimization study of 3 starting doses of ponatinib.Blood. 2022;140(1):1495-1497. doi:10.1182/blood-2022-157822
7. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABLinhibitor for chronic myeloid leukemia, potently inhibits the T315Imutant and overcomes mutation-based resistance. Cancer Cell.2009;16(5):401-412. doi:10.1016/j.ccr.2009.09.028
8. Valent P, Hadzijusufovic E, Hoermann G, et al. Risk factorsand mechanisms contributing to TKI-induced vascular eventsin patients with CML. Leuk Res. 2017;59:47-54. doi:10.1016/j.leukres.2017.05.008
9. Gover-Proaktor A, Granot G, Shapira S, et al. Ponatinib reducesviability, migration, and functionality of human endothelial cells.Leuk Lymphoma. 2017;58(6):1455-1467. doi:10.1080/10428194.2016.1239258
10. Gover-Proaktor A, Granot G, Pasmanik-Chor M, et al. Bosutinib,dasatinib, imatinib, nilotinib, and ponatinib differentially affect thevascular molecular pathways and functionality of human endothelial cells.Leuk Lymphoma. 2019;60(1):189-199. doi:10.1080/10428194.2018.1466294
11. Singh AP, Glennon MS, Umbarkar P, et al. Ponatinib-inducedcardiotoxicity: delineating the signalling mechanisms and potential rescuestrategies. Cardiovasc Res. 2019;115(5):966-977. doi:10.1093/cvr/cvz006
12. Talbert DR, Doherty KR, Trusk PB, Moran DM, Shell SA, Bacus S. A Multi-parameter in vitro screen in human stem cell-derived cardiomyocytesidentifies ponatinib-induced structural and functional cardiac toxicity.Toxicol Sci. 2014;143(1):147-155. doi:10.1093/toxsci/kfu215
13. Shelburne N, Adhikari B, Brell J, et al. Cancer treatment-relatedcardiotoxicity: current state of knowledge and future research priorities. JNatl Cancer Inst. Sep 2014;106(9):dju232 doi:10.1093/jnci/dju232
Article available in :
Volume 1, Issue 4, 2023
Page : 104-106
https://doi.org/10.51271/JCHOR-0023
Article Information
Received : 01 Nov 2023
Accepted : 17 Nov 2023
Published : 30 Nov 2023
Corresponding Author :

Mert Tokatlı: Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkiye

[email protected]
Citation : Tokatlı M, Gecici NN, Ergin MI, et al. Ponatinib-induced dilated cardiomyopathy: a case report. J Curr Hematol Oncol Res. 2023;1(4):104-106.

Read: 129
Download : 2754
Cited: 0
_Footer